1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Advancing Research into the Cause and Treatment of Rare Skin Diseases is sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Advancing Translational Sciences (NCATS), National Institute of Environmental Health Sciences (NIEHS) (NIH). This NIH highlighted topic aims to facilitate research on rare skin diseases, with a focus on projects involving multidisciplinary teams of basic, translational, and clinical scientists.
Get alerted about grants like this
Save a search for “National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Center for Advancing Translational Sciences (NCATS), National Institute of Environmental Health Sciences (NIEHS) (NIH)” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Advancing Research into the Cause and Treatment of Rare Skin Diseases | Grants & Funding U.S. Department of Health and Human Services National Institutes of Health Advancing Research into the Cause and Treatment of Rare Skin Diseases When beginning your next investigator-initiated application, consider the following NIH highlighted topic.
The area of science described below is of interest to the listed NIH Institutes, Centers, and Offices (ICOs). This is not a notice of funding opportunity (NOFO). Apply through an appropriate NIH Parent Funding Announcement or another broad NIH opportunity available on Grants.
gov . Learn how to interpret and use Highlighted Topics . Expiration Date: April 2, 2027 It is estimated that 1 in 10 US residents suffer from a rare disease, most of which present in childhood.
For many of these diseases, the underlying causes are either unknown or incompletely understood. Further, most of these diseases (approximately 95%) lack FDA-approved treatment, leading to significant childhood morbidity and mortality. This topic aims to facilitate research on rare skin diseases.
Projects including multidisciplinary teams of basic, translational, and clinical scientists are of particular interest. Topics of interest include, but are not limited to: Environmental triggers (pollutants, UV exposure, allergens) of disease development. Diagnostic markers and biomarkers (e.g., disease progression and treatment response).
In vivo and in vitro disease models for mechanistic studies and drug screening, including those proposed in the New Approach Methodologies (NAM) NIH initiative (e.g., human cell-based organoids, 3D culture systems, tissue or organ on-a-chip) (NIH Standardized Organoid Modeling (SOM) Center | National Institutes of Health (NIH)) Genetic studies identifying the causes of rare skin diseases.
Identification of molecular and cellular disease pathways and potential therapeutic targets. Commonalities across diseases for developing new therapies that can target multiple disorders.
FDA-approved drugs repurposed to treat rare diseases Cell and gene therapy approaches Revertant mosaicism as a window into treatment strategies and disease reversal mechanisms Examples of diseases of interest include (but are not limited to): Erythropoietic Protoporphyria Recessive Dystrophic Epidermolysis Bullosa Central Scientific Contact: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) NIAMS encourages research into rare skin diseases, including genetic causes and disease mechanisms.
The goal is to develop new therapies. Multidisciplinary and team science approaches are of particular interest. National Center for Advancing Translational Sciences (NCATS) NCATS develops s olutions t hat a id m any t ranslational r esearch e fforts (STAMTRE).
Specifically, we are interested in supporting research focused on STAMTRE that are applicable to multiple rare skin diseases, including but not limited to: Gene therapy/gene editing Basket trial protocols, or Therapeutics targeting s h a red m olecular e tiologies (SaME therapeutics). In contrast, applications focused on individual rare skin diseases would not be of interest for NCATS funding.
IC may give special consideration to support meritorious applications in this topic area. National Institute of Environmental Health Sciences (NIEHS) NIEHS is interested in epidemiology, mechanistic (including toxicology, gene-environment interactions), and appropriate in vitro, in vivo, and computational studies that examine the role of the exposome/environmental exposures in the development and/or progression of rare skin diseases.
Examples of environmentally relevant exposures include industrial chemicals or manufacturing byproducts, metals, pesticides, ambient heat, and air pollutants and other inhaled toxicants.
Office of Research on Women's Health (ORWH) The Office of Autoimmune Disease Research in the Office of Research on Women’s Health (OADR-ORWH) is interested in supporting autoimmune disease-associated rare skin conditions with a focus on addressing current gaps in the autoimmune disease research portfolio.
Topics of interest include: As well as skin conditions associated with systemic autoimmune diseases, including scleroderma, dermatomyositis, celiac disease, inflammatory bowel disease, and systemic lupus erythematosus The engagement of people living with and at risk of autoimmunity, family members, clinicians, and allied health professionals is strongly encouraged to ensure research has direct relevance to human health.
This office does not award grants. Applications must be relevant to the objectives of at least one of the participating Institutes or Centers listed in this topic. Victoria Shanmugam, MBBS, FRCP, FACR, CCD For technical issues E-mail OER Webmaster
Based on current listing details, eligibility includes: Investigators with projects focused on rare skin diseases. Multidisciplinary teams are of particular interest. Applications focused on individual rare skin diseases would not be of interest for NCATS funding. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates See official notice Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is April 2, 2027. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
AAI Career Awards is a grant from the American Association of Immunologists (AAI) that honors members for outstanding research and career achievement. Through multiple award tracks — including the Lifetime Achievement Award, Distinguished Service Award, Distinguished Fellows program, Public Service Award, and Vanguard Award — AAI recognizes immunologists at every career stage who have made exceptional scientific, institutional, or public-policy contributions. Nominations originate from the AAI Council and designated committees. The program celebrates careers defined by scientific excellence, service to the immunology community, and contributions to public advocacy, minority recruitment in the sciences, and disease research. Deadline is September 10, 2025.